title: Trazodone and alcohol relapse: a retrospective study following residential treatment.
abstract: Trazodone is one of the most commonly prescribed hypnotic medications in patients with sleep disturbances in alcohol recovery. A recent study concluded that treating insomnia with trazodone in patients with alcohol dependence might impede improvements in alcohol consumption and lead to increased drinking when trazodone is stopped. We set out to investigate the relationship between trazodone use during alcoholism treatment and relapse rates in patients who were discharged from a residential alcohol treatment program. We retrospectively reviewed records of patients with a diagnosis of alcohol dependence in a residential addiction treatment center from 2005 to 2008 and analyzed the association of trazodone use at discharge and alcohol relapse at 6 months. We also assessed the association between trazodone use and relapse at 6 months adjusting for sex, drug dependence, nonsubstance use Axis I psychiatric diagnoses, patient self-report of difficulties with sleep, and anti-dipsotropic medication use at discharge and evaluated pair-wise interactions of trazodone use with the adjustment variables. Of 283 patients eligible for inclusion, 85 (30%) were taking trazodone at discharge. Older age, self-reported sleep problems, and having a nonsubstance use Axis I psychiatric diagnosis were associated with trazodone use. After discharge, 170 (60%) subjects responded to follow-up efforts. Neither intent to treat nor responder only analysis revealed any association between trazodone use and relapse. Our retrospective study of a complex patient population discharged from a residential treatment setting did not find an association between trazodone use at discharge and relapse rates at 6 months.
authors: Department of Psychiatry, Mayo Clinic, Rochester, Minnesota, USA. kolla.bhanuprakash@mayo.edu
authors: Bhanu Prakash
authors: BP
authors: Kolla
authors: Terry D
authors: TD
authors: Schneekloth
authors: Joanna M
authors: JM
authors: Biernacka
authors: Mark A
authors: MA
authors: Frye
authors: Meghna P
authors: MP
authors: Mansukhani
authors: Daniel K
authors: DK
authors: Hall-Flavin
authors: Victor M
authors: VM
authors: Karpyak
authors: Larissa L
authors: LL
authors: Loukianova
authors: Timothy G
authors: TG
authors: Lesnick
authors: David
authors: D
authors: Mrazek
mesh_terms: D000437:Alcoholism / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D001523:Mental Disorders / Q000150:complications / Q000175:diagnosis; D008875:Middle Aged; D012114:Residential Treatment / Q000379:methods / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D055502:Secondary Prevention; D012737:Sex Factors; D012893:Sleep Wake Disorders / Q000150:complications / Q000188:drug therapy*; D014196:Trazodone / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D006993:Hypnotics and Sedatives; D014196:Trazodone